Discovery of common human genetic variants of GTP cyclohydrolase 1 (GCH1) governing nitric oxide, autonomic activity, and cardiovascular risk

Lian Zhang,1 Fangwen Rao,1 Kuixing Zhang,1 Srikrishna Khandrika,1 Madhusudan Das,1 Sucheta M. Vaingankar,1 Xuping Bao,1 Brinda K. Rana,2 Douglas W. Smith,2 Jennifer Wessel,1 Rany M. Salem,1 Juan L. Rodriguez-Flores,1 Sushil K. Mahata,1,4 Nicholas J. Schork,2,5 Michael G. Ziegler,1 and Daniel T. O’Connor1,4,6

1Department of Medicine, 2Department of Psychiatry, and 3Department of Biology, UCSD School of Medicine, San Diego, California, USA. 4VA San Diego Healthcare System, San Diego, California, USA. 5Center for Human Genetics and Genomics and 6Department of Pharmacology, UCSD School of Medicine, San Diego, California, USA.

GTP cyclohydrolase 1 (GCH1) is rate limiting in the provision of the cofactor tetrahydrobiopterin for biosynthesis of catecholamines and NO. We asked whether common genetic variation at GCH1 alters transmitter synthesis and predisposes to disease. Here we undertook a systematic search for polymorphisms in GCH1, then tested variants’ contributions to NO and catecholamine release as well as autonomic function in twin pairs. Renal NO and neopterin excretions were significantly heritable, as were baroreceptor coupling (heart rate response to BP fluctuation) and pulse interval (1/heart rate). Common GCH1 variant C+243T in the 3′-untranslated region (3′-UTRs) predicted NO excretion, as well as autonomic traits: baroreceptor coupling, maximum pulse interval, and pulse interval variability, though not catecholamine secretion. In individuals with the most extreme BP values in the population, C+243T affected both diastolic and systolic BP, principally in females. In functional studies, C+243T decreased reporter expression in transfected 3′-UTRs plasmids. We conclude that human NO secretion traits are heritable, displaying joint genetic determination with autonomic activity by functional polymorphism at GCH1. Our results document novel pathophysiological links between a key biosynthetic locus and NO metabolism and suggest new strategies for approaching the mechanism, diagnosis, and treatment of risk predictors for cardiovascular diseases such as hypertension.

Introduction

GTP cyclohydrolase 1 (GCH1) catalyzes the first and rate-limiting step in tetrahydrobiopterin (BH4) biosynthesis (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI31093DS1). BH4 is an essential cofactor for several transmitter biosynthetic pathway enzymes, including tyrosine hydroxylase (TH) and NOSs, as well as phenylalanine hydroxylase and tryptophan hydroxylase. Studies in vitro indicate that BH4 levels are tightly linked to hydroxylation of L-tyrosine (to L-DOPA) and BH4 bioavailability modulates catecholamine synthesis (1).

The human GCH1 locus experiences rare natural inactivating mutations with profound consequences: such mutations cause 2 disorders: autosomal dominant hereditary progressive dystonia/DOPA-responsive dystonia (HPD/DRD) and autosomal recessive GCH1-deficient hyperphenylalaninemia (HPA). Biochemical characterizations of these diseases demonstrate lower cerebrospinal fluid levels of BH4, neopterin, and homovanillic acid, with low levels of TH activity in the striatum (2). A mouse model for dominantly inherited GTP cyclohydrolase deficiency also showed low brain levels of BH4, catecholamines, serotonin, and their metabolites together with low levels of TH activity within the striatum (3).

The gaseous transmitter NO, derived from 3 NOS isoforms, plays a key role in vascular tone, and alterations in NO production influence endothelium-dependent vasodilation and BP. Previous studies in cultured cells showed that GCH1 inhibition lowers BH4 levels, leading to decreased NO production (4, 5). Exogenous BH4 in the spontaneously (genetic) hypertensive rat can prevent development of elevated BP (6).

Does more common genetic variation at GCH1 also cause enzymatic activity changes of NOS or TH in humans? Might such genetic variation alter endothelial or autonomic activity and thus predispose to cardiovascular disease? To answer these questions, we explored common allelic variation at the GCH1 locus. To probe the impact of GCH1 variation on disease pathways, we resequenced approximately 1.2 kbp of 3′ promoter as well as all 6 exons and adjacent intronic regions for rare and common variants in DNA from 64 ethnically diverse subjects as well as 171 pairs of twins. The twins were phenotyped for biochemical and physiological traits likely to be influenced by variation in GCH1, including transmitters, baroreceptor indices, and BP. The study tested whether GCH1 single nucleotide polymorphisms (SNPs) influenced human endothelial or autonomic activity. Twin pairs enabled us to study whether GCH1 allelic variation contributed to heritable control of the circulation.

Nonstandard abbreviations used: BH4, tetrahydrobiopterin; DBP, diastolic BP; DZ, dizygotic; GCH1, GTP cyclohydrolase 1; h, heritability; LD, linkage disequilibrium (D); MZ, monozygotic; SBP, systolic BP; TH, tyrosine hydroxylase; UTR, untranslated region.

Conflict of interest: The authors have declared that no conflict of interest exists.

Citation for this article: J. Clin. Invest. 117:2658–2671 (2007). doi:10.1172/JCI31093.
Results

**GCH1 genomics: systematic human polymorphism discovery**

To identify genetic variants in **GCH1** that might alter its function, we resequenced all 6 exons and adjacent intronic regions, as well as approximately 1.2 kbp of 5′ promoter adjacent to exon 1 (Supplemental Table 1) in DNA from 64 unrelated human subjects. Later we resequenced **GCH1** from an additional 171 pairs of twins collected as part of our cardiorenal phenotypic studies.

Figure 1A shows sequences conserved between mouse and human **GCH1** were visualized with VISTA (http://genome.lbl.gov/vista/index.shtml). Location of common (upper) and rare (lower) SNPs relative to exons and conserved noncoding sequences is indicated by position. Red lines represent nonsynonymous SNPs, while black rods represent synonymous SNPs. Nucleotides in red in the chimpanzee haplotype indicate the minor allele in the human sequence. Computationally reconstructed haplotypes are indicated, along with their relative frequencies in ethnogeographic groups within our sample population. Nucleotide deletions in haplotype sequences are indicated by an asterisk. *n* = 42 variants were discovered; *n* = 13 were common (≥5%), while *n* = 29 were rare (<5%).

**Figure 1**

Polymorphism at **GCH1**: distribution across the gene. (A) Local genomic region. **GCH1** resequencing strategy and identified variants. Sequences conserved between mouse and human **GCH1** were visualized with VISTA (http://genome.lbl.gov/vista/index.shtml). Location of common (upper) and rare (lower) SNPs relative to exons and conserved noncoding sequences is indicated by position. Red lines represent nonsynonymous SNPs, while black rods represent synonymous SNPs. Nucleotides in red in the chimpanzee haplotype indicate the minor allele in the human sequence. Computationally reconstructed haplotypes are indicated, along with their relative frequencies in ethnogeographic groups within our sample population. Nucleotide deletions in haplotype sequences are indicated by an asterisk. *n* = 42 variants were discovered; *n* = 13 were common (≥5%), while *n* = 29 were rare (<5%). (B) Functional domains and coding region SNPs. The distribution of variants across **GCH1** exons and functional protein domains is illustrated. ATG, translational start codon; Cap, transcriptional initiation site; ORF, open reading frame.

Thirty-nine biallelic SNPs, 2 short (1- to 2-bp) insertion/deletions, and 1 trinucleotide repeat/microsatellite were identified in our initial sample of 64 subjects. Among the 39 SNPs, 11 were located in the approximately 1.2-kbp proximal promoter, 2 in coding regions (1 synonymous, 1 nonsynonymous; both rare), 18 in the untranslated regions (UTRs), and 8 in exon-adjacent intronic regions. Twelve SNPs were common (minor allele frequency ≥5%), including 3 in the **GCH1** proximal promoter, 7 in the UTRs, and 2 in the introns. One of the 2 insertion/deletions was located in the proximal promoter, while 1 was in the 3′-UTRs (relatively common, at 6.3%). The trinucleotide repeat/microsatellite located in the 3′-UTRs was rare.

Applying the HAP algorithm (7) to 12 common (minor allele frequency >5%) variants and 1 common insertion/deletion across **GCH1**, we inferred 12 haplotypes (Figure 1A). The 3 most common haplo-
types accounted for 74.3% of chromosomes examined; the most common haplotype (GTGCCCACTTT**C, where ** is the 2-bp AT insertion in exon 6) was frequent (at 58.8%) in the white population but less common (at 33.3%) in samples from black individuals. The third most common haplotype (most likely ancestral, ACGCCCATTT**C) was more common in black than white subjects (21.7% versus 7.4%).

Figure 1B illustrates $GCH1$ functional domains and coding region SNPs in the resequenced 64 individuals. Both of the 2 coding region polymorphisms were unusual (minor allele frequency <0.6%), and only 1 specified an amino acid substitution (Arg184Cys).

Supplemental Table 1 presents $GCH1$ SNP results in the original discovery sample (all 64 individuals unrelated): 39 SNPs, 2 insertion/deletions, and 1 trinucleotide repeat/microsatellite were identified. Of these, 12 were relatively common variants: G–811A at 42.2%, T–756C at 42.2%, G–592A at 5.5%, C18T at 8.6%, C109T at 8.6%, C635T at 7.0%, A37633C at 6.3%, C59038T at 21.1%, T59694A at 6.3%, T59695A at 6.3%, T59700A at 6.3%, the AT 2-bp insertion/deletion (59,892–59,893) at 6.3%, and C60025T at 5.5%. Among the 39 SNPs, 9 were purine/purine (A/G) transitions, and 14 were pyrimidine/pyrimidine (C/T) transversions, while 16 were purine/pyrimidine (R/Y) transversions.

SNP genotype frequencies differed substantially by ethnicity: greater numbers of relatively common (minor allele frequency >5%) SNPs were identified in black (35 such SNPs) than whites.
individuals (13 such SNPs) (Supplemental Table 1). GCH1 contains a single trinucleotide repeat (microsatellite) polymorphism: (TCC)$_n$, at 3–4 copies of the repeat ([TCC])$_n$, within the 3' UTRs; (TCC)$_n$/([TCC])$_n$ heterozygosity was the only diploid genotype observed in these subjects.

**Linkage disequilibrium across the GCH1 locus**
Pairwise linkage disequilibrium (LD) between common SNPs across GCH1 was quantified as parameter $D'$, scaled from 0 to 1. Figure 2 shows a Graphical Overview of Linkage Disequilibrium (GOLD) plot across GCH1 in subjects of European (Figure 2A) or sub-Saharan African (Figure 2B) ancestry, revealing 2 blocks of particularly high LD ($D' > 0.9$) at the 5' (promoter to intron 1) and 3' (exon 6) regions of the gene in black individuals. Of note, common polymorphism C59038T in the 3' UTRs of exon 6 displayed virtually no LD with other, more 5' variants in subjects of European ancestry (Figure 2A).

**GCH1 haplotypes**
Table 1 describes the GCH1 haplotype distribution in white twins. GCH1 haplotypes were imputed by HAP using all SNPs (2n = 684 chromosomes/n = 342 individuals) in subjects of European ancestry. None-human primate nucleotides at those positions are also shown (each corresponding to human haplotype 4). Haplotypes 1 and 2 (top rows) were the 2 most frequent haplotypes, with sufficient power for statistical marker-on-trait analyses.

**Table 1**
Haplotype distribution in GCH1

<table>
<thead>
<tr>
<th>Haplotype no.</th>
<th>Nucleotide at bp position (Cap site +1)</th>
<th>Frequency (2n = no. of chromosomes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>G T G C C</td>
<td>0.645 (441)</td>
</tr>
<tr>
<td>2</td>
<td>A C G C T</td>
<td>0.120 (82)</td>
</tr>
<tr>
<td>3</td>
<td>A C A G</td>
<td>0.086 (60)</td>
</tr>
<tr>
<td>4</td>
<td>A C G C C</td>
<td>0.070 (48)</td>
</tr>
<tr>
<td>5</td>
<td>G T G C T</td>
<td>0.050 (34)</td>
</tr>
<tr>
<td>6</td>
<td>A C A G</td>
<td>0.015 (10)</td>
</tr>
<tr>
<td>7</td>
<td>A T G C C</td>
<td>0.009 (6)</td>
</tr>
<tr>
<td>8</td>
<td>A T A G C</td>
<td>0.003 (2)</td>
</tr>
<tr>
<td>9</td>
<td>G T A G C</td>
<td>0.001 (1)</td>
</tr>
<tr>
<td>Chimpanzee (haplotype 4)</td>
<td>A C G C C</td>
<td>(2)</td>
</tr>
<tr>
<td>Gorilla (haplotype 4)</td>
<td>A C G C C</td>
<td>(2)</td>
</tr>
<tr>
<td>Orangutan (haplotype 4)</td>
<td>A C G C C</td>
<td>(2)</td>
</tr>
</tbody>
</table>

GCH1 haplotypes were imputed by HAP using all SNPs (2n = 684 chromosomes/n = 342 individuals) in subjects of European ancestry. None-human primate nucleotides at those positions are also shown (each corresponding to human haplotype 4). Haplotypes 1 and 2 (top rows) were the 2 most frequent haplotypes, with sufficient power for statistical marker-on-trait analyses.

**Heritability in twins**
Renal/urinary NO and neopterin excretions were significantly heritable (at $h^2 = 39.7 \pm 7.01\%$ and $h^2 = 44.2 \pm 8.13\%$ [where $h^2$ is heritability]; both $P < 0.0001$ (Table 3). Observed values for $b^2$ of body mass index, basal BP, heart rate, and urinary catecholamines also displayed significant heritability, consistent with our previous reports (8). Heritability was substantial for vital signs, with SBP ($h^2 = 45.1\% \pm 7.0\%$; $P = 0.0001$) and DBP ($h^2 = 51.3\% \pm 6.2\%$; $P = 0.00001$) more heritable than heart rate ($h^2 = 30.5\% \pm 7.8\%$; $P = 0.00015$). Pulse interval (1/heart rate) values were also heritable, whether expressed as maximum values, minimum values, or variability. Heritability was significant for baroreceptor coupling, at $b^2 = 54.8\% \pm 6.15\%$ ($P < 0.0001$).

**Pleiotropy (shared heritability) in twins: genetic covariance of NO excretion**
Since other heritable (Table 3) biochemical traits correlated with urine NO excretion (Supplemental Table 2), we tested such traits for shared genetic determination (pleiotropy) with the NO trait (Supplemental Table 2).

**Genetic covariance.** The results indicate that urine NO excretion shares significant genetic determination with the correlated trait of urinary neopterin excretion (genetic covariance [$\rho_G$] = 0.493 ± 0.128; $P = 0.00183$). Environmnetal covariance.** The results (Supplemental Table 2) also indicate that urinary NO excretion shares significant environmental codetermination with the correlated traits of urinary neopterin excretion (environmental covariance [$\rho_E$] = 0.326 ± 0.0754; $P = 0.000069$) and urinary epinephrine excretion ($\rho_E = 0.266 ± 0.0801; P = 0.00165$).

**GCH1 associations with biochemical and physiological traits in twins**
Across GCH1, we began by testing whether any of the 5 common individual polymorphisms in GCH1 (Figures 1 and 2, and Supplemental Table 1) affected any of the biochemical traits in twins dependent upon GCH1 activity (Supplemental Figure 1): secretion levels of neopterin, NO, or catecholamines. Only GCH1 variant C59038T (in the 3'-UTRs, at C+243T) predicted any of these traits (Table 4). Of note, this 3'-UTRs variant displayed virtually no LD ($D' < 0.1$) with the promoter region variants in the European ancestry sample (Figure 2A).

**GCH1 C59038T (3'-UTRs C+243T).** The 3'-UTRs variant predicted NO excretion ($P = 0.0086$), though not neopterin or catecholamine secretion (Table 4). Significant C+243T associations were also found for autonomic traits: baroreceptor coupling ($P = 0.0414$), maximum pulse interval (i.e., minimum heart rate; $P = 0.0075$),

---

**Haplotype distribution in GCH1**

<table>
<thead>
<tr>
<th>Haplotype no.</th>
<th>Nucleotide at bp position (Cap site +1)</th>
<th>Frequency (2n = no. of chromosomes)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>G T G C C</td>
<td>0.645 (441)</td>
</tr>
<tr>
<td>2</td>
<td>A C G C T</td>
<td>0.120 (82)</td>
</tr>
<tr>
<td>3</td>
<td>A C A G</td>
<td>0.086 (60)</td>
</tr>
<tr>
<td>4</td>
<td>A C G C C</td>
<td>0.070 (48)</td>
</tr>
<tr>
<td>5</td>
<td>G T G C T</td>
<td>0.050 (34)</td>
</tr>
<tr>
<td>6</td>
<td>A C A G</td>
<td>0.015 (10)</td>
</tr>
<tr>
<td>7</td>
<td>A T G C C</td>
<td>0.009 (6)</td>
</tr>
<tr>
<td>8</td>
<td>A T A G C</td>
<td>0.003 (2)</td>
</tr>
<tr>
<td>9</td>
<td>G T A G C</td>
<td>0.001 (1)</td>
</tr>
<tr>
<td>Chimpanzee (haplotype 4)</td>
<td>A C G C C</td>
<td>(2)</td>
</tr>
<tr>
<td>Gorilla (haplotype 4)</td>
<td>A C G C C</td>
<td>(2)</td>
</tr>
<tr>
<td>Orangutan (haplotype 4)</td>
<td>A C G C C</td>
<td>(2)</td>
</tr>
</tbody>
</table>

GCH1 haplotypes were imputed by HAP using all SNPs (2n = 684 chromosomes/n = 342 individuals) in subjects of European ancestry. None-human primate nucleotides at those positions are also shown (each corresponding to human haplotype 4). Haplotypes 1 and 2 (top rows) were the 2 most frequent haplotypes, with sufficient power for statistical marker-on-trait analyses.
and pulse interval variability (heart rate variability; \( P = 0.0498 \)).

The 3′-UTRs polymorphism did not associate with basal (resting, average) BP or heart rate in these predominantly normotensive subjects (Table 4).

In Figure 3, A and B, these relationships are portrayed graphically. Figure 3A plots baroreflex coupling as a function of NO synthesis. C+243T minor allele homozygotes (T/T diploid genotype) displayed decreases in both NO excretion and baroreflex coupling (Figure 3A); the T allele thus seemed to act recessively on both of these traits. Figure 3B illustrates the joint effects of C+243T on both traits. C+243T did not affect heart rate or BP variability in the high frequency (0.15–0.4 Hz; parasympathetic) domain.

**Genetic interactions of GCH1: sex and age**

Since sex affects renal NO excretion (females with greater values than males), and age affects baroreceptor coupling (younger individuals with greater values than older individuals) (Table 2), we evaluated whether the GCH1 C+243T effects on NO or baroreceptor coupling (Figure 3A) were influenced by or interacted with sex or age. Genotype and age interacted (\( P = 0.029 \); Figure 4A) to affect NO, with the most prominent difference between sexes in C/C (major allele) homozygotes. Genotype and age interacted (\( P < 0.0001 \); Figure 4B) to affect baroreceptor coupling, with the most prominent age effects in the homozygote classes (C/C or T/T).

**GCH1 haplotypes and twin traits**

We approached haplotype effects by testing whether haplotype copy number (0, 1, or 2 per genome) across the GCH1 locus influenced biochemical or physiological traits in twins. This approach is feasible (i.e., may have sufficient power) for the most common haplotypes in a population (here, haplotypes 1 [GTGCC] and 2 [ACGCT]). However, copy number of neither haplotype 1 nor haplotype 2 showed significant effects on NO, catecholamines, neopterin, or any of the physiological traits (all \( P > 0.05 \)).

**GCH1 3′-UTRs variant C+243T and hypertension**

GCH1 variant C+243T was scored in \( n = 1,049 \) individuals selected from the extreme values of DBP in a large primary care population of more than 53,000 individuals (Figure 5). The C+243T diploid genotype had a significant overall effect on both DBP (\( P = 0.008 \)) and SBP (\( P = 0.008 \)). However, the genotype

---

### Table 2

Descriptive statistics for the twin study population

<table>
<thead>
<tr>
<th>Trait</th>
<th>All</th>
<th>Age&lt;40</th>
<th>Age≥40</th>
<th>Male</th>
<th>Female</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>Mean ± SEM</td>
<td>Mean ± SEM</td>
<td>Mean ± SEM</td>
<td>Mean ± SEM</td>
<td>Mean ± SEM</td>
</tr>
<tr>
<td>Demographic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age, yr</td>
<td>342</td>
<td>40.95 ± 0.9</td>
<td>26.2 ± 0.53</td>
<td>54.2 ± 0.78</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sex, M/F</td>
<td>342</td>
<td>M/F 75/267</td>
<td>M/F 44/118</td>
<td>M/F 31/149</td>
<td>0.102</td>
</tr>
<tr>
<td>Physical BMI, kg/m²</td>
<td>342</td>
<td>24.8 ± 0.26</td>
<td>23.4 ± 0.31</td>
<td>26.1 ± 0.39</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Hemodynamic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>336</td>
<td>131.1 ± 0.87</td>
<td>126.4 ± 1.0</td>
<td>135.3 ± 1.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>DBP, mmHg</td>
<td>336</td>
<td>71.5 ± 0.54</td>
<td>68.3 ± 0.68</td>
<td>74.43 ± 0.77</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>336</td>
<td>70.1 ± 0.68</td>
<td>70.5 ± 1.12</td>
<td>69.74 ± 0.8</td>
<td>0.601</td>
</tr>
<tr>
<td>Autonomic</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baroreflex coupling at 0.05–0.15 Hz, ms/mmHg</td>
<td>339</td>
<td>14.8 ± 0.89</td>
<td>19.6 ± 1.63</td>
<td>10.5 ± 0.68</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Pulse (R-R) interval, ms/beat</td>
<td>342</td>
<td>Maximum</td>
<td>1,156 ± 32.0</td>
<td>1,181 ± 45.9</td>
<td>1,134.1 ± 44.8</td>
</tr>
<tr>
<td></td>
<td>Mean</td>
<td>846 ± 7.5</td>
<td>842 ± 10.8</td>
<td>850.51 ± 10.4</td>
<td>0.573</td>
</tr>
<tr>
<td></td>
<td>Minimum</td>
<td>621 ± 17.8</td>
<td>576 ± 14.6</td>
<td>660.45 ± 30.9</td>
<td>&lt;0.0179</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>74.3 ± 3.92</td>
<td>84.4 ± 5.23</td>
<td>65.3 ± 5.69</td>
<td>0.0147</td>
</tr>
<tr>
<td>Biochemical</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine NO, nmol/mg creatinine</td>
<td>338</td>
<td>1.26 ± 0.06</td>
<td>1.24 ± 0.09</td>
<td>1.28 ± 0.07</td>
<td>0.702</td>
</tr>
<tr>
<td>Urine neopterin, μmol/mol creatinine</td>
<td>338</td>
<td>168 ± 5.55</td>
<td>162 ± 10.4</td>
<td>172.8 ± 4.78</td>
<td>0.332</td>
</tr>
<tr>
<td>Urine dopamine, ng/g creatinine</td>
<td>317</td>
<td>24,323 ± 8197</td>
<td>15,670 ± 369</td>
<td>32,498 ± 15,934</td>
<td>0.306</td>
</tr>
<tr>
<td>Urine epinephrine, ng/g creatinine</td>
<td>316</td>
<td>13,484 ± 362</td>
<td>12,610 ± 474</td>
<td>14,315 ± 538</td>
<td>&lt;0.0185</td>
</tr>
<tr>
<td>Urine norepinephrine, ng/g creatinine</td>
<td>316</td>
<td>29,244 ± 804</td>
<td>23,219 ± 635</td>
<td>34,971 ± 1,238</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

\( \mu = \) mean, \( \sigma = \) standard deviation.

Significant \( P < 0.05 \) differences are underlined.

\( n = 342 \) individuals from \( n = 171 \) white (European ancestry) twin pairs; \( n = 118 \) MZ pairs (23 M/M, 95 F/F); and 53 DZ pairs (9 M/M, 33 F/F, 11 M/F). Data represent mean ± SEM, by generalized estimating equations (GEEs). For age effects, values were sex adjusted; for sex effects, values were age adjusted. Significant \( P < 0.05 \) differences are underlined.
Table 3
Heritability ($h^2 = V_p/V_v$) of autonomic function in twins: biochemical and physiological traits

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>Heritability, %</th>
<th>n (individuals)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Physical</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>82.2 ± 2.96</td>
<td>306</td>
</tr>
<tr>
<td><strong>Hemodynamic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>45.1 ± 6.96</td>
<td>301</td>
</tr>
<tr>
<td>DBP, mmHg</td>
<td>51.3 ± 6.20</td>
<td>301</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>30.5 ± 7.79</td>
<td>301</td>
</tr>
<tr>
<td><strong>Autonomic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baroreflex coupling at 0.05–0.15 Hz, ms/mmHg</td>
<td>54.8 ± 6.15</td>
<td>306</td>
</tr>
<tr>
<td>Pulse (R-R) interval, ms/beat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum (log10)</td>
<td>27.3 ± 9.71</td>
<td>306</td>
</tr>
<tr>
<td>Mean</td>
<td>61.9 ± 5.73</td>
<td>298</td>
</tr>
<tr>
<td>Minimum (log10)</td>
<td>27.8 ± 8.66</td>
<td>306</td>
</tr>
<tr>
<td>SD (log10)</td>
<td>22.7 ± 8.49</td>
<td>306</td>
</tr>
<tr>
<td><strong>Biochemical</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine NO, nmol/mg creatinine</td>
<td>39.7 ± 7.01</td>
<td>306</td>
</tr>
<tr>
<td>Urine neopterin, umol/mol creatinine</td>
<td>44.2 ± 8.13</td>
<td>306</td>
</tr>
<tr>
<td>Urine dopamine, ng/g creatinine (log10)</td>
<td>32.8 ± 7.46</td>
<td>285</td>
</tr>
<tr>
<td>Urinary epinephrine, ng/g creatinine</td>
<td>68.1 ± 5.20</td>
<td>284</td>
</tr>
<tr>
<td>Urinary norepinephrine, ng/g creatinine</td>
<td>44.4 ± 7.07</td>
<td>284</td>
</tr>
</tbody>
</table>

Heritability ($\pm$ SEM) is the percentage of phenotypic variation ($V_p$) explained by additive genetic factors ($V_a$). Values are age and sex adjusted. $P$ value is the significance of the heritability value (difference from 0, i.e., no heritability). Significant ($P < 0.05$) values are underlined.

Table 3 provides a detailed analysis of the heritability of various physiological and biochemical traits in twins, showing how genetic factors contribute to the variation observed in these traits. The traits include physical measures like BMI, hemodynamic parameters such as systolic blood pressure (SBP) and diastolic blood pressure (DBP), as well as autonomic functions like baroreflex coupling.

The study indicates that genetic factors play a significant role in the variation of these traits, with heritability values ranging from 27.3% to 61.9% for different parameters. The data supports the genetic basis of autonomic function and biochemical markers, highlighting the importance of heredity in the regulation of physiological processes.

The effect on DBP displayed a significant gene-by-sex interaction ($P = 0.046$). Indeed, when males and females were analyzed separately, females showed significant genotype effects upon both DBP ($P = 0.002$) and SBP ($P = 0.007$), while no effects were found for males alone ($P = 0.22–0.24$) (Figure 5A). The authors note that these effects are consistent with the observed differences in biological pathways and mechanisms between males and females.

The GCH1 3′-UTRs variant C+243T: evidence of functional consequences in vitro

GCH1 3′-UTRs variant C+243T: evidence of functional consequences in vitro

The study explores the functional consequences of the GCH1 3′-UTRs variant C+243T both in vitro and in vivo. In vitro experiments were conducted on reporter plasmid pGL3-Promoter, downstream of the luciferase reporter gene, to assess the impact of this variant on transcription and translation efficiency.

The results indicate that the C+243T variant significantly affects the efficiency of luciferase activity, with a notable decrease in luciferase expression compared to the wild-type variant. This finding suggests that the C+243T variant may alter the stability or processing of the mRNA, affecting the translation efficiency of the GCH1 protein.

The authors also performed phylogenetic analysis to understand the evolutionary context of this variant, suggesting that the C+243T variant may have been under selective pressure, possibly due to its role in maintaining proper function or in adaptation to environmental changes.

Other genotypes in pathways controlling catecholamines or NO

The study further investigates the role of other genotypes in the pathways controlling catecholamines or NO, highlighting the complexity of these pathways and the potential for multiple genetic factors to influence their function.

The research article concludes by emphasizing the importance of understanding the genetic basis of autonomic function and the role of micro-RNA binding sites in modulating gene expression. The findings contribute to a larger understanding of the genetic mechanisms underlying physiological responses and may have implications for the development of targeted therapies for cardiovascular disorders.
Critical role of GCH1 in NO and catecholamine metabolism

GCH1 encodes the first and rate-limiting enzyme in the synthesis of BH4, an essential cofactor for TH and NOS in the catecholamine and NO production pathways, respectively, thus playing a

Both decreased heart rate variability (15, 16) and increased resting heart rate (17) are risk indicators for premature cardiovascular death. Our results in twin pairs document the role of heredity in these risk predictors (Table 3): baroreflex coupling at 54.8% ± 6.2% (P < 1 × 10^-7), overall heart rate variability (pulse interval SD) at 22.7% ± 8.5% (P = 0.0054), and minimum heart rate (maximum pulse interval) at 27.8 ± 8.7% (P = 0.013).

Finally, our genetic results define a role for a specific DNA variant (GCH1 C+243T) in a crucial pathway (Supplemental Figure 1) in triggering a pleiotropic series of effects on cardiovascular risk (Figures 3 and 5).

Heredity clearly influences human longevity (18–20), though the responsible genetic variants are not well defined in humans. Our twin results serve to quantify heritable contributions (Table 3) to risk predictors for premature mortality, such as heart rate variability and heart rate, thus refining the tractability of such traits to further genetic investigation. Of note for the consequences of C+243T on longevity, the polymorphism seemed to interact with age in determining baroreceptor coupling (Figure 4B), with the most profound age effects on the trait seen in major (C/C) or minor (T/T) allele homozygotes.

Discussion

Overview

In this study, we undertook systematic polymorphism discovery at GCH1, revealing 13 common variants spanning the exons and proximal promoter. Allele frequencies and patterns of LD varied by ethnicity. In a series of twins phenotyped for autonomic and renal function. The influence of NO on the baroreceptor has been investigated in experimental animals: NO• acts in brainstem nuclei to inhibit sympathetic outflow while enhancing parasympathetic outflow (13). Overexpression of NOS in the rostral ventrolateral medulla causes sympathetic activity, BP, and heart rate to fall in experimental hypertension (14). Decreased baroreflex coupling in T/T homozygotes resulted in decreased overall heart rate (or pulse interval) variability (Figure 3B), eventuating in a higher minimum heart rate (maximum pulse interval; Figure 3B).

Cardiovascular consequences of GCH1 polymorphism: NO, age, autonomic function, and risk predictors

GCH1 C+243T was associated with not only NO production but also baroreflex coupling (Figure 3A); in particular, T/T homozygotes displayed not only diminished NO but also decreased baroreceptor function. The influence of NO on the baroreceptor has been investigated in experimental animals: NO• acts in brainstem nuclei to inhibit sympathetic outflow while enhancing parasympathetic outflow (13). Overexpression of NOS in the rostral ventrolateral medulla causes sympathetic activity, BP, and heart rate to fall in experimental hypertension (14). Decreased baroreflex coupling in T/T homozygotes resulted in decreased overall heart rate (or pulse interval) variability (Figure 3B), eventuating in a higher minimum heart rate (maximum pulse interval; Figure 3B).

Table 4

Effects of GCH1 3′-UTRs variant C+243T (C59038T) diploid genotype on biochemical and physiological traits in twin pairs

<table>
<thead>
<tr>
<th>Phenotype</th>
<th>C+243T (C59038T) diploid genotype</th>
<th>Genotypes affect on trait</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SEM</td>
<td>χ²</td>
</tr>
<tr>
<td>n (subjects)</td>
<td>C/C</td>
<td>C/T</td>
</tr>
<tr>
<td>Hemodynamic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SBP, mmHg</td>
<td>132.6 ± 1.4</td>
<td>131.7 ± 1.7</td>
</tr>
<tr>
<td>DBP, mmHg</td>
<td>71.7 ± 0.9</td>
<td>72.5 ± 1.2</td>
</tr>
<tr>
<td>Heart rate, bpm</td>
<td>69.1 ± 1.1</td>
<td>69.4 ± 1.3</td>
</tr>
<tr>
<td>Autonomic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baroreflex coupling at 0.05–0.15 Hz, ms/mmHg</td>
<td>15.1 ± 1.95</td>
<td>14.7 ± 1.4</td>
</tr>
<tr>
<td>Pulse (R-R) interval, ms/beat</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maximum (log_{10})</td>
<td>1.233 ± 0.65</td>
<td>1.107 ± 0.57</td>
</tr>
<tr>
<td>Basal</td>
<td>854 ± 14.5</td>
<td>845 ± 18.7</td>
</tr>
<tr>
<td>Minimum (log_{10})</td>
<td>634 ± 27.4</td>
<td>661 ± 71.3</td>
</tr>
<tr>
<td>SD (log_{10})</td>
<td>82.9 ± 6.9</td>
<td>70.5 ± 6.29</td>
</tr>
<tr>
<td>Biochemical</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine neopterin, μmol/mol creatinine</td>
<td>157 ± 7.5</td>
<td>148 ± 7.4</td>
</tr>
<tr>
<td>Urine NO, mmol/mg creatinine</td>
<td>1.16 ± 0.08</td>
<td>1.23 ± 0.13</td>
</tr>
<tr>
<td>Urine dopamine, ng/g creatinine (log_{10})</td>
<td>43,991 ± 26,613</td>
<td>24,307 ± 10,184</td>
</tr>
<tr>
<td>Urine epinephrine, ng/g creatinine</td>
<td>13,274 ± 559</td>
<td>14,107 ± 961</td>
</tr>
<tr>
<td>Urine norepinephrine, ng/g creatinine</td>
<td>29,369 ± 1061</td>
<td>27,476 ± 1,455</td>
</tr>
</tbody>
</table>

Results were obtained by GEEs.
A crucial role in the sympathoadrenal and endogenous nitrovasodilator systems (Supplemental Figure 1). GCH1 was isolated as the first causative gene for L-DOPA-responsive dystonia (21). Profound GCH1 deficiency in humans, as occurs after unusual inactivating mutations (Gly201Glu or Asp134Val) in homozygotes, results in widespread disturbances of neuropsychiatric function, such as autosomal recessive dystonia (22). The hph-1 mouse model of GCH1 deficiency (3) also displays reductions in levels of BH4, NO, catecholamines, serotonin, and their metabolites (23). GCH1 haplotypes also reportedly predict pain sensitivity in humans (24); we did not explore pain in our subjects. Finally, the effect of GCH1 genotype on BP in hypertension seemed to be confined to female subjects (28, 29). Since both sex (Table 2) and GCH1 genotype (Table 4) influenced NO, we tested and found a significant gene-by-sex interaction in control of this trait (Figure 4A), with the most pronounced sex differences seen in major allele (C/C) homozygotes. The penetrance of profoundly inactivating mutations at GCH1 seems to be quite sex dependent, with phenotypes occurring more frequently in female carriers (30), while circulating mononuclear cell GCH1 enzymatic activity is higher in females than males (21). We did not measure GCH1 activity in these subjects. Despite these effects, our data do not include GCH1 activity, and the sex differences seen in major allele (C/C) homozygotes. The penetrance of profoundly inactivating mutations at GCH1 seems to be quite sex dependent, with phenotypes occurring more frequently in female carriers (30), while circulating mononuclear cell GCH1 enzymatic activity is higher in females than males (21). We did not measure GCH1 activity in these subjects. The effect of GCH1 genotype on BP in hypertension seemed to be confined to female subjects (Figure 5).

**Figure 3**

GCH1 3′-UTRs (C+243T) polymorphism effects on biochemical and physiological traits in twin pairs. (A) Baroreflex coupling as a function of renal NO (NO) production. Univariate effects of C+243T on each trait are shown. Baroreflex coupling was determined in the low-frequency domain (0.05–0.15 Hz). Renal NO production was normalized to the concentration of creatine in the same urine sample. Univariate NO: $\chi^2 = 9.50$, $P = 0.0086$. Univariate baroreflex: $\chi^2 = 6.37$, $P = 0.0411$. Alleles: C = 80.2%, T = 19.8%. Hardy-Weinberg equilibrium (HWE), $\chi^2 = 1.76$, $P = 0.184$. (B) Minimum resting heart rate as a function of heart rate variability. Univariate effects of C+243T on each trait are shown. Heart rate variability, in the resting state, was determined as pulse interval (PI) SD (ms) over 5 minutes of monitoring in the time domain. Minimum resting heart rate was determined as maximum (max) PI (ms) during the same monitoring period. Univariate PI SD: $\chi^2 = 6.0$, $P = 0.0498$. Univariate PI max: $\chi^2 = 9.78$, $P = 0.0075$. Alleles: C = 80.2%, T = 19.8%. HWE, $\chi^2 = 1.76$, $P = 0.184$.

**Strengths and weaknesses of this study: coupling the twin method and systematic polymorphism discovery with adrenergic and disease phenotyping**

**Twin phenotyping protocol.** Here we exploited the classical twin design (31, 32). Twin data offer the unique advantage of direct measurement of heritability ($h^2$), the fraction of phenotypic variance accounted for by genetic variance, a logical estimator of the tractability of any trait to genetic investigation. Since twins are randomly sampled from the population, genetic conclusions drawn from twin studies are likely to be generalizable to the population from which they were sampled (31). Multiple autonomic phenotypes in the twins, both biochemical and physiological, allowed for inference of an integrated picture of the effects of particular genetic variants at GCH1.

**Systematic polymorphism discovery.** LD mapping is an increasingly powerful tool for exploring genetic determinants of disease (33). However, the LD approach requires the fulfillment of many assumptions (34), including substantial LD between marker (surrogate) and trait (causative) alleles. Here we took another approach: systematic polymorphism discovery at a candidate genetic locus. This approach enables direct testing of marker-on-genetic locus. This approach enables direct testing of marker-on-
A. Finally, we demonstrated that the 3'-UTRs variant C→T is itself functional: C→T conversion in a transfected 3'-UTRs reporter plasmid (Supplemental Figure 2) diminished gene expression in a fashion directionally appropriate to the action of the T allele in vivo to diminish NO production (Figure 6).

Caveats. While we conducted systematic variant discovery in both black (sub-Saharan Africa) and white subjects (European ancestry) (Supplemental Table 1 and Supplemental Figure 3), the studies on physiology and disease were analyzed only in white subjects, initially to avoid the potentially spurious effects of population stratification on genetic trait associations (35). Only additional studies can determine whether the associations in white subjects are generalizable to other population groups. In studies of complex traits in the “post-genomic” era, the effects of several genetic variants may be evaluated on multiple traits, raising the specter of false positive (type I or α) statistical errors. We approached this issue in several ways: haplotyping (Table 1 and Figure 2) allowed us to evaluate several genetic variants simultaneously. Similarly, we studied the simultaneous effects of a single genetic variant upon multiple traits (Table 4 and Figures 5 and 6); since such traits are correlated, a simple Bonferroni correction would have been inappropriately conservative. We undertook permutation tests where possible (Figure 5B), documenting the independence of our findings from statistical distribution assumptions. Finally, we documented the effects of GCH1 variation on physiological traits in 2 different samples (twins and population BP extremes). Nonetheless, in the absence of full replication, any such genetic marker-on-trait results should not be characterized as definitive.

NO. The measurement of urinary nitrate/nitrite excretion is intended to provide an accessible index of renal NO production for consideration of its heritable determination by genetic variation at biosynthetic loci. However, urine nitrate/nitrite excretion is influenced by environment, in the form of dietary ingestion (36), as well as by heredity; our twin sample displayed substantial heritability of this trait (at h² = 39.7% ± 7.0%; χ² = 23.4, P = 0.0001). While we conducted systematic variant discovery in both black (sub-Saharan Africa) and white subjects (European ancestry) (Supplemental Table 1 and Supplemental Figure 3), the studies on physiology and disease were analyzed only in white subjects, initially to avoid the potentially spurious effects of population stratification on genetic trait associations (35). Only additional studies can determine whether the associations in white subjects are generalizable to other population groups. In studies of complex traits in the “post-genomic” era, the effects of several genetic variants may be evaluated on multiple traits, raising the specter of false positive (type I or α) statistical errors. We approached this issue in several ways: haplotyping (Table 1 and Figure 2) allowed us to evaluate several genetic variants simultaneously. Similarly, we studied the simultaneous effects of a single genetic variant upon multiple traits (Table 4 and Figures 5 and 6); since such traits are correlated, a simple Bonferroni correction would have been inappropriately conservative. We undertook permutation tests where possible (Figure 5B), documenting the independence of our findings from statistical distribution assumptions. Finally, we documented the effects of GCH1 variation on physiological traits in 2 different samples (twins and population BP extremes). Nonetheless, in the absence of full replication, any such genetic marker-on-trait results should not be characterized as definitive.

Risk indicators and disease in the population. Careful autonomic phenotyping of twins allowed us to define effects of GCH1 variation on such cardiovascular disease risk predictors as baroreflex dysfunction, reduced heart rate variability, and increased minimum heart rate (Figure 3). In turn, the availability of genomic DNA from subjects with the most extreme BPs in the population enabled us to establish a disease (hypertension) association for GCH1 3'-UTRs C→T (Figure 5).

Sex. Since in classical twin studies, subjects are randomly sampled from the population (31), both sexes are represented in such studies. Likewise, the availability of a large primary care population (31) enabled us to study the consequences of GCH1 variation on hypertension in both males and females. For both biochemical (Figure 4A) and physiological (Figures 3 and 4) intermediate traits, as well as the disease trait of hypertension (Figure 5), sex effects on the traits were prominent, and gene-by-sex interactions were observed (Figure 4A and Figure 5), reinforcing the value of informative sex representation in studies of cardiovascular disease (28).

Functional characterization of C→T variant. Finally, we demonstrated the effects of the 3'-UTRs variant C→T is itself functional: C→T conversion in a transfected 3'-UTRs reporter plasmid (Supplemental Figure 2) diminished gene expression in a fashion directionally appropriate to the action of the T allele in vivo to diminish NO production (Figure 6).

Haplotypes. Imputation of phase from diploid genotype data is inherently uncertain and occasionally prone to misclassification; the haplotype method we used assigns the 2 most likely haplotypes to each individual (7). While emerging haplotype

Figure 4

GCH1 3'-UTRs C→T genotype interactions on trait determination in twin pairs: sex and age. Interactions were suspected based on the independent effects of sex and age on crucial traits (Table 3) and then tested by generalized estimating equations (GEEs). (A) Genotype-by-sex interaction on renal NO excretion. GEE χ² = 9.50, P = 0.029. (B) Genotype-by-age interaction on baroreflex coupling in the low-frequency domain (0.05–0.15 Hz). Subjects were dichotomized as older or younger than 40 years. GEE χ² = 23.4, P = 0.0001.
methods consider uncertainty in phasing (37, 38), such methods
have not yet been coupled with the computational needs of cor-
related twin pair statistics.

Conclusions and perspectives
Human NO production is substantially heritable (at $h^2 = 39.7%$
$\pm 7.0%; P = 4 \times 10^{-7}$; Table 3), displaying joint genetic determi-
nation (Figures 3 and 6 and Supplemental Table 2) with auto-
nomic activity. We further conclude that NO secretion is con-
trolled in part by genetic variation in the pathway encoding NO
synthesis, especially at the classically rate-limiting step, GCH1.
The trait-associated allele in the GCH1 3′-UTRs (+243T) seems
to be functionally active (Figure 6) and may have arisen early in
the human lineage (Supplemental Figure 3). The results point to
novel pathophysiological links between a key biosynthetic locus
and NO metabolism (Figure 8 and Supplemental Figure 1) and
suggest new strategies to approach the mechanism, diagnosis,
and treatment of risk indicators of cardiovascular disease.

Hypothesis schematic. A schematic formulating our results into
a global hypothesis is presented in Figure 8, outlining the role
of intermediate phenotypes and the GCH1 variant C59038T
(in the 3′-UTRs, at C+243T) in the determination of hypertension
via the initial intermediary of NO secretion. While the
pathway outlined is hypothetical, it may frame questions for
future experimentation.

Implications for pathophysiology/mechanism, prediction/diagnosis,
treatment. Our results suggest that the NO pathway is centrally
involved in the early pathogenesis of cardiac diseases beginning
in healthy individuals, perhaps initially by altering baroreceptor
function (Table 4 and Figures 3 and 6). Genetic determination
of biochemical (Figure 3A) and physiological (Figure 3) traits in
this pathway (Supplemental Figure 4) suggests that treatments
targeting the pathway (such as BH4; ref. 39) might be beneficial
in preventing later cardiac diseases if administered to subjects
at specific genetic risk. Our results also raise the possibility that
genetic profiling of patients with impaired endothelial or auto-
nomic activity might yield practical pharmacogenetic predic-
tors of patients most likely to benefit from such therapies (39).
Finally, our results raise the possibility that profiling subjects
for particular biosynthetic polymorphisms would provide an
index of susceptibility to cardiovascular disease. This prediction
awaits testing in appropriate longitudinal cohorts.

Figure 5
Hypertension. Intermediate phenotype–associated GCH1
variant C+243T was typed in n = 1,049 subjects selected
from the most extreme DBPs (high and low) in a primary
care population of more than 53,000 individuals. (A) DBP
and SBP as a function of diploid genotype. Results were
analyzed by 2-way ANOVA, factoring for genotype, sex,
and genotype-by-sex interaction. DBP, ANOVA: geno-
type $F = 4.81, P = 0.008$; sex $F = 0.150, P = 0.698$; gene-by-
sex $F = 3.06, P = 0.046$; alleles C = 81%, T = 19%. HWE:
$\chi^2 = 0.724, P = 0.395$; males alone: $F = 1.43, P = 0.240$;
females alone: $F = 6.21, P = 0.002$. SBP, ANOVA: geno-
type $F = 4.84, P = 0.008$; sex $F = 1.49, P = 0.700$; gene-by-
sex $F = 2.19, P = 0.112$; alleles C = 81%, T = 19%. HWE:
$\chi^2 = 0.724, P = 0.395$; males alone: $F = 1.52, P = 0.220$;
females alone: $F = 5.06, P = 0.007$. (B) BP status (high
versus low) as a function of diploid genotype. Subjects
were grouped by sex and C+243T diploid genotype.
Results were analyzed by permutation testing on 3-by-2 con-
tingency tables. Gene-by-diag-
nosis permutation: females, $P = 0.00082$; males, $P = 0.155$. 

Figure 6
Effect of GCH1 3′-UTRs polymorphism on gene expression in vitro. 3′-UTRs expression plasmids were transfected into PC12 chromaffin cells. After continued cell growth for 8–24 hours after transfection, cells were harvested for assay of firefly luciferase as well as the cotransfected Renilla luciferase reporter pRL-CMV. Results of triplicate transfections are expressed as the ratio of firefly/Renilla luciferase activity and were analyzed by 2-way ANOVA, factoring for the effects of 3′-UTRs and time. 2-Way repeated measures ANOVA: plasmid (3′-UTRs) F = 12.04, P = 0.013; time F = 163.6, P < 0.001.

Methods

Subjects and clinical characterization
Initially, a series of n = 64 unrelated individuals was studied by resequencing of GCH1 for systematic polymorphism discovery: n = 34 of European ancestry (white) and n = 30 sub-Saharan African ancestry (black). A series of n = 171 twin pairs was also studied by resequencing the GCH1 locus.

Ethnicity was established by self-identification by the participants as well as their parents and grandparents. None of the subjects had a history of renal failure. Definitions of subject characteristics are according to previous reports from our laboratory (40). Subjects were volunteers from southern California, and each subject gave informed, written consent; the protocol was approved by the UCSD institutional review board.

Twin pairs. We recruited a series of twin pairs, taking advantage of a large population-based twin registry in southern California (8, 41) as well as by advertisement (8). These twin individuals were all of European ancestry, identified DZ twins or SNP data (11–177 SNPs) as well as the TH (TAT) microsatellite (8) for self-reported MZ twins. The diet was the subjects’ customary unrestricted intake of nutrients and fluids.

Genomics
Genomic DNA was prepared from leukocytes in EDTA-anticoagulated blood, using PureGene extraction columns (Gentra; Qiagen) as described previously (42). Public draft human (43) and mouse (44) genome sequences were obtained from the UCSC Genome Bioinformatics website (http://genome.ucsc.edu) and used as a scaffold for primer design and sequence alignment. The base position numbers were from NCBI GCHI source clones NM_00016 (isoform 1), NT_0026437, and NP_000152. Promoter positions were numbered with upstream (−) the GCH1 exon 1 start (cap) site. The following PCR primers were designed by Primer3 (45) to span approximately 1,200 bp of the proximal promoter and each of the 6 exons, as well as to include 50–100 bp of flanking intronic sequence: promoter 1, left primer 5′-GGTGGTCTTATTGTTGTTT-3′, right primer 5′-GTCCTTTCCCAA-GATGTTGTT-3′; promoter 2, left primer 5′-GAGTTGAGTTGGTGTTT-3′, right primer 5′-CCGAGTTAAGGCGACATTTA-3′; promoter 3, left primer 5′-GTCGAGGTTGGTTTTTAC-3′, right primer 5′-GTCGAACCTGCTTAGATACAA-3′; exon 1, left primer 5′-GCGGGG-CATAAAAGGAG-3′, right primer 5′-AGTAAAGCCAGCTCCGAA-3′; exon 2, left primer 5′-CTCTGGTCTCCCTTCTTCT-3′, right primer 5′-GGTCTTATCTTGAGAGGCTTC-3′; exon 3, left primer 5′-AGCATCCAGATGTTTTCAG-3′, right primer 5′-ATGAGGCGAGGAGAAGG-3′; exon 4, left primer 5′-ATTTCCTTCTTGACGCCCCACT-3′, right primer 5′-GAAAATGTGAGGAAATGTGCAA-3′; exon 5, left primer 5′-CGCCACCTGCTTAGATACAA-3′; exon 6, left primer 5′-CTCTGGTCTCCCTTCTTCT-3′, right primer 5′-GTCGAGGTTGGTTTTTAC-3′, right primer 5′-GTCGAACCTGCTTAGATACAA-3′; exon 1, left primer 5′-CTCTGGTCTCCCTTCTTCT-3′, right primer 5′-GTCGAGGTTGGTTTTTAC-3′, right primer 5′-GTCGAACCTGCTTAGATACAA-3′; exon 2, left primer 5′-CTCTGGTCTCCCTTCTTCT-3′, right primer 5′-GTCGAGGTTGGTTTTTAC-3′, right primer 5′-GTCGAACCTGCTTAGATACAA-3′; exon 3, left primer 5′-CTCTGGTCTCCCTTCTTCT-3′, right primer 5′-GTCGAGGTTGGTTTTTAC-3′, right primer 5′-GTCGAACCTGCTTAGATACAA-3′; exon 4, left primer 5′-CTCTGGTCTCCCTTCTTCT-3′, right primer 5′-GTCGAGGTTGGTTTTTAC-3′, right primer 5′-GTCGAACCTGCTTAGATACAA-3′.

Figure 7
The CHG1 isoform 1 (NT_00016) 3′-UTRs spans 2,009 bp (human chromosome 14, 54378476–54380484). The alignment shown spans 60 bp flanking the polymorphism (at position 54380242 on chromosome 14). The polymorphic base (human C+243T) is shown in uppercase bold type. Asterisk indicates that the position is identical in all primates shown. The chimpanzee, gorilla, and orangutan sequences were newly determined here.
Intermediate phenotypes. In the “intermediate phenotype” schema, biochemical traits (such as NO production) are postulated to be determined earlier and more proximately by genotype (such as GCH1 3′-UTRs C>c243T) than are physiological traits (such as heart rate variability and resting heart rate) and, ultimately, late-penetrance disease (such as cardiovascular disease, hypertension, or sudden death). Here the concept is illustrated by the findings at GCH1 in the current study: the GCH1 3′-UTRs variant C>c243T initially alters NO production, subsequently influencing baroreceptor coupling and heart variability, later minimum resting heart rate, and finally basal BP in the population.

Biochemical phenotyping: catecholamines and NO metabolites

Plasma and urine catecholamines were measured radioenzymatically (51). Biochemical phenotyping: catecholamines and NO metabolites

Plasma and urine catecholamines were measured radioenzymatically (51). Noninvasive brachial arterial cuff BPs were determined earlier and more proximately by genotype (such as GCH1 3′-UTRs C>c243T) than are physiological traits (such as heart rate variability and resting heart rate) and, ultimately, late-penetrance disease (such as cardiovascular disease, hypertension, or sudden death). Here the concept is illustrated by the findings at GCH1 in the current study: the GCH1 3′-UTRs variant C>c243T initially alters NO production, subsequently influencing baroreceptor coupling and heart variability, later minimum resting heart rate, and finally basal BP in the population.

Biochemical phenotyping: catecholamines and NO metabolites

Plasma and urine catecholamines were measured radioenzymatically (51). Noninvasive brachial arterial cuff BPs were determined earlier and more proximately by genotype (such as GCH1 3′-UTRs C>c243T) than are physiological traits (such as heart rate variability and resting heart rate) and, ultimately, late-penetrance disease (such as cardiovascular disease, hypertension, or sudden death). Here the concept is illustrated by the findings at GCH1 in the current study: the GCH1 3′-UTRs variant C>c243T initially alters NO production, subsequently influencing baroreceptor coupling and heart variability, later minimum resting heart rate, and finally basal BP in the population.

Physiological/autonomic phenotyping in vivo

Prolonged recording of BP and heart rate. Noninvasive brachial arterial cuff BPs were obtained in seated subjects with an oscillometric device, as previously described (52). BP (in mmHg) and pulse interval (R-R interval or heart period, in ms/beat) were then recorded continuously and noninvasively for 5 minutes in seated subjects with a radial artery applanation device and dedicated sensor hardware (Colin Pilot; Colin Instruments) and software (ATLAS, WR Medical Electronics Co.; and Autonomic Nervous System, Tonometric Data Analysis [ANs-TDA], Colin Instruments), calibrated every 5 minutes against ipsilateral brachial arterial pressure with a cuff sphygmomanometer (8). Heart rate was recorded continuously with thoracic ECG electrodes to the Colin Pilot. Average, maximum, and minimum values, as well as coefficients of variation, were calculated for BP and pulse interval using the ANs-TDA software.

Baroreceptor coupling in the frequency domain. Power spectra for SBP, DBP, and pulse (R-R) interval were obtained during the 5-minute recording, using the ANs-TDA software, by Fourier transformation of data from the time domain into the frequency domain (53). Spectral power is the variance (i.e., [SD]^2) of the parameter in a particular frequency domain; e.g., for R-R interval, in milliseconds, spectral power is in milliseconds squared. The low-frequency or classical baroreceptor domain (0.05-0.15 Hz) reflects a mixture of parasympathetic and sympathetic activity. In this frequency domain, coupling of R-R interval power to SBP power (ms^2/mmHg^2) was computed as \frac{1}{2}[(R-R power, ms^2)/[SBP power/mmHg^2]) = baroreflex sensitivity (ms/mmHg) in the frequency domain.

Hypertension

We studied \( n = 1,049 (n = 497 \text{ male}, n = 552 \text{ female}) \) white (European ancestry) subjects drawn from \( n = 53,078 \) individuals (\( n = 27,475 \text{ females}, n = 25,538 \text{ males} \)), recruited from a large primary care (Kaiser Permanente) population in San Diego, as previously described (54). In this primary care population, approximately 81% attended the clinic, and approximately 46% consented to participation in the study, with collection of blood for preparation of genomic DNA. From consented participants, the subjects in this study were selected, based upon measurement of DBP, to represent the highest and lowest DBP percentiles in that population. \( n = 509 \) subjects were chosen for the highest DBPs, while \( n = 540 \) subjects were chosen for the lowest DBPs. The ages of the high- and low-BP groups were not different (low BP 59 ± 0.5 years, high BP 59 ± 0.4 years [\( P = 0.94 \)]); to accomplish this, low BP-individuals (SBP/DBP: 111 ± 0.6 mmHg/55 ± 0.3 mmHg) were selected from the bottom 4.8th percentile of DBP, while the high-BP group (SBP/DBP: 153 ± 0.6 mmHg/100 ± 0.8 mmHg) was selected from the top 4.9th percentile of DBP. Both SBP and DBP differed significantly between the BP extreme groups (\( P < 0.0001 \) and \( P < 0.0001 \)). Forty-one percent of patients in the high-BP group were taking one or more antihypertensive medications (including 15% on diuretics and 19% on angiotensin-converting enzyme [ACE] inhibitors), while none in the low-BP group were on such treatment.

GCH1 3′-UTRs: functional consequences in vitro

The GCH1 3′-UTR was amplified from a cloned bacterial artificial chromosome (BAC) target region, in BAC RP11-304L20, which spans the GCH1 gene, obtained from the BACpac Resource at Children’s Hospital of Oakland Research Institute. The 2,009-bp 3′-UTRs was amplified with PCR primers incorporating XbaI restriction sites, facilitating ligation into the unique XbaI site in luciferase reporter plasmid pGL3-Promoter (Promega); in this plasmid, the XbaI site is just downstream (3′) of the firefly luciferase reporter open reading frame and upstream of the polyadenylation signal (pA from SV40). Correct orientation (5′→3′) of the insert was verified with asymmetric digestion by MfeI (C′AATTG), which cuts the insert at base 88 and the vector at base 2,103 (within the pA cassette). Creation of the C′→3′ polymorphism was done by site-directed mutagenesis (QuikChange; Stratagene). After plasmid growth under ampicillin selection in E. coli and purification on columns (QIAGEN), supercoiled plasmid DNA was transfected into PC12 chromaffin cells using established protocols and Superfect cationic lipid reagent (QIAGEN) (55), along with the transfection efficiency control plasmid pRL-CMV, encoding the Renilla luciferase reporter under control of the CMV promoter (Promega). After transfection and cell growth over an 8- to 24-hour time course, cells were lysed for sequential measurement of the 2 luciferase enzymatic activities (firefly and Renilla) with the dual luciferase assay
system (Promega) in an ultrasonitve luminometer (AutoLumat LB 953; Berthold Technologies). Luciferase results are expressed as firefly/Renilla activity ratios from triplicate transfections.

**Statistics**

Descriptive statistics. Descriptive statistics (mean, SEM) were computed across all the twins, using general estimating equations (GEEs; PROC GENMOD) in SAS (Statistical Analysis System), creating an exchangeable correlation matrix to account for correlated trait values within each twin pair (56).

Heritability of phenotype expression in vivo. Heritability ($h^2$) is the fraction of phenotypic variance accounted for by genetic variance ($h^2 = V_g/V_t$). Estimates of $h^2$ were obtained using the variance component method implemented in the Sequential Oligogenic Linkage Analysis Routine (SOLAR) package (57). This method maximizes the likelihood of the estimate assuming a multivariate normal distribution of phenotypes in twin pairs (MZ versus DZ) with a mean on a particular set of explanatory covariates. The null hypothesis ($h^2 = 0$) is tested by comparing the full model, which assumes genetic variation, and a reduced model, which assumes no genetic variation, using a likelihood ratio test. Covariates (sex and age) that were significant at $P < 0.05$ were retained in the heritability model. Before analyses in SOLAR, exploratory descriptive statistics were computed for each trait, and if trait values displayed excessive kurtosis, they were log$_e$-transformed to achieve kurtosis less than 0.8.

Haplotypes and LD. Haplotypes were inferred from unphased diploid genotypes with the likelihood-based method HAP (7) available at http://research.calit2.net/hap. We inferred the GCH1 haplotypes using 5 common (minor allele frequency >5%) SNPs discovered by resequencing n = 64 unrelated individuals (n = 128 chromosomes) chosen to span 2 diverse ethnic groups: white (European ancestry) and black (sub-Saharan African ancestry). Blocks of LD were displayed using Graphical Observation of Linkage Disequilibrium (58).

Association. Association studies were performed for the GCH1 common alleles (minor allele frequency >5%). Each study subject was categorized according to diploid genotype at a biallelic SNP locus, or carrier status (2, 1, or 0 copies) of most frequent haplotypes.

Permutation. To explore the effects of GCH1 3′-UTRs variant C+243T on BP status (hypertensive versus normotensive) in model-free fashion, without relying on standard asymptotic assumptions, we also employed more computationally intensive permutation (exact) tests (59) on 3-by-2 contingency tables (diploid genotype by BP status) as described at http://www.physics.ucsb.edu/statst/exact.html.

**Phylogeny.** Haplotype phylogeny plots were reconstructed using an extension of the HAP algorithm (7). For common SNPs (each minor allele frequency >10%), the phylogeny over the haplotypes was computed by optimizing a probabilistic model that assumes exponential population growth after a population bottleneck. Under this assumption, any variants after the bottleneck occur in haplotypes that are also present in the modern population. Haplotype variants that have no intermediates between them (i.e., that vary by ≈2 SNPs) are assumed to originate before the bottleneck and are therefore “ancestral.” “Common” variants are single mutation or recombination events away from the ancestral variants; such events are thus likely to have happened after a major population bottleneck. The algorithm identifies “recent” haplotype variants by considering rare (<5%) haplotypes and explaining them with either a single gene conversion, mutation, or recombination event from the common haplotypes. The remaining haplotypes are clustered into ancestral groups, and any recombinants (resulting from meiotic crossover events) are identified. The algorithm is implemented as an extension to the HAP program (7), available online at http://diego.ucsd.edu/hap/html/. A $P$ value of less than or equal to 0.05 was considered significant.

**Acknowledgments**

This work was funded by grants from the Department of Veterans Affairs and the NIH, including General Clinical Research Center (GCRC) grant RR00827. We appreciate the assistance of the GCRC nursing and core laboratory staff in accomplishing this study.

Received for publication November 29, 2006, and accepted in revised form May 18, 2007.

Address correspondence to: Daniel T. O’Connor or Michael G. Ziegler, Department of Medicine, UCSD School of Medicine, 9500 Gilman Drive, La Jolla, California 92093-0838, USA. Phone: (858) 534-0661; Fax: (858) 534-0626; E-mail: doconnor@ucsd.edu (D.T. O’Connor); mziegler@ucsd.edu (M.G. Ziegler).

Lian Zhang, Fangwen Rao, and Kuixing Zhang contributed equally to this work.


